|
健保碼及健保價 |
|
See related Lantus[蘭德仕] information |
|
|
|
製造商 |
Sanofi-aventis |
|
代理/經銷商 |
Sanofi-aventis |
|
成份 |
Insulin glargine |
|
適應症 |
Treatment of adults, adolescents & children ≥ 6 years with diabetes mellitus, where treatment with insulin is required. |
|
用量 |
Administer SC once daily at the same time everyday. Dose & timing of dose should be individually adjusted. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
注意事項 |
Not the insulin of choice for the treatment of diabetic ketoacidosis. Children < 6 years, renal & hepatic impairment. Hypoglycemia. Patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain, or with proliferative retinopathy. Intercurrent illness. May impair ability to drive or operate machinery. Pregnancy & lactation. |
|
不良反應 |
Hypoglycemia, lipohypertrophy, inj site reactions.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Increased blood-sugar-lowering effect when used with oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics. Decreased blood-sugar-lowering effect when used with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics, thyroid hormones, atypical antipsychotics & protease inhibitors. β-blockers, clonidine, lithium salts or alcohol. Guanethidine & reserpine.
View more drug interactions with Lantus[蘭德仕] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Lantus 筆式注射劑 |
|
Lantus (Optiset) 100 u/1 mL x 3 mL |
|
Lantus (Solostar) 100 u/1 mL x 3 mL |
|
|
Lantus 注射劑 |
|
Lantus (Vial) 100 u/1 mL x 10 mL |
|
|
|
Manufacturer: |
Sanofi-aventis |
|
Distributor: |
Sanofi-aventis
|
|
|
|
